Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Santhera Pharmaceuticals Holding AG
  6. News
  7. Summary
    SANN   CH0027148649

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
Delayed Swiss Exchange  -  05/27 11:31:38 am EDT
1.330 CHF   +2.31%
04/29Santhera will Publish its 2021 Annual Report by June 3, 2022, and Hold its Annual General Meeting on June 29, 2022
GL
04/29Santhera will Publish its 2021 Annual Report by June 3, 2022, and Hold its Annual General Meeting on June 29, 2022
AQ
04/13Santhera Pharmaceuticals Names New Chief Medical Officer
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Meeting

12/15/2021 | 07:18am EDT
share with twitter
share with LinkedIn
share with facebook

(MORE TO FOLLOW) Dow Jones Newswires

December 15, 2021 07:17 ET (12:17 GMT)

All news about SANTHERA PHARMACEUTICALS HOLDING AG
04/29Santhera will Publish its 2021 Annual Report by June 3, 2022, and Hold its Annual Gener..
GL
04/29Santhera will Publish its 2021 Annual Report by June 3, 2022, and Hold its Annual Gener..
AQ
04/13Santhera Pharmaceuticals Names New Chief Medical Officer
MT
04/13Santhera Appoints Shabir Hasham as Chief Medical Officer and Member of the Executive Ma..
AQ
04/13Santhera Pharmaceuticals Holding AG Appoints Shabir Hasham as Chief Medical Officer and..
CI
03/29Santhera, ReveraGen Submit Rolling New Drug Application For Duchenne Muscular Dystrophy..
MT
03/29Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the T..
AQ
03/29Santhera Pharmaceuticals and Reveragen Biopharma, Inc Announces Initiation of Rolling N..
CI
03/15Santhera Pharmaceuticals Secures Future Financing With Issuance Of Treasury Shares
MT
03/15Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Musc..
DJ
More news
Financials
Sales 2021 8,00 M 8,37 M 8,37 M
Net income 2021 -39,0 M -40,8 M -40,8 M
Net Debt 2021 - - -
P/E ratio 2021 -1,85x
Yield 2021 -
Capitalization 48,5 M 50,7 M 50,7 M
Capi. / Sales 2021 6,07x
Capi. / Sales 2022 5,51x
Nbr of Employees 86
Free-Float 82,9%
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,33 CHF
Average target price 5,50 CHF
Spread / Average Target 314%
EPS Revisions
Managers and Directors
Dario Eklund Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Elmar J. Schnee Chairman
Shabir Hasham Chief Medical Officer
Philipp Gutzwiller Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SANTHERA PHARMACEUTICALS HOLDING AG0.00%51
MERCK KGAA-21.50%83 006
KYOWA KIRIN CO. LTD.-12.92%11 543
SK BIOPHARMACEUTICALS CO., LTD.-9.77%5 492
YUHAN CORPORATION-3.70%3 252
INDIVIOR PLC25.37%2 855